Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJTOG0105: MVP vs Irinotecan/Carbo vs Paclitaxel/Carbo in Stage III NSCLC
NCT00144053Phase 3Completed
- Sponsor
- West Japan Oncology Group
- Start
- Apr 2001
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 3 trial of irinotecan, paclitaxel, carboplatin in non-small cell lung cancer (NSCLC), sponsored by West Japan Oncology Group. Started Apr 2001; status: completed.
02
Drugs
irinotecanpaclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00144053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144053.